Natasha Daughtrey, partner, Intellectual Property Litigation and Life Sciences Disputes at law firm Goodwin, discusses intellectual property strategy around large molecules, CAR-T and biosimilars. BioXconomy (BX): While large molecules, CAR-T therapies, and biosimilars represent distinct therapeutic modalities, what common intellectual property challenges or strategic considerations unite these three areas? BX: For investors and pharmaceutical companies evaluating acquisition or licensing opportunities in large molecules, CAR-T therapies, or biosimilars, what are the essential IP due diligence priorities? BX: For early-stage biotechnology companies developing large molecules, CAR-T therapies, or biosimilars with limited resources, what IP protection strategies should be prioritized to maximize asset value and attract investment? BX: What are the most frequent and consequential mistakes made during IP due diligence in transactions involving large molecules, CAR-T therapies, or biosimilars?